265 related articles for article (PubMed ID: 18672895)
1. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.
Walse B; Dufe VT; Svensson B; Fritzson I; Dahlberg L; Khairoullina A; Wellmar U; Al-Karadaghi S
Biochemistry; 2008 Aug; 47(34):8929-36. PubMed ID: 18672895
[TBL] [Abstract][Full Text] [Related]
2. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection.
Fritzson I; Svensson B; Al-Karadaghi S; Walse B; Wellmar U; Nilsson UJ; da Graça Thrige D; Jönsson S
ChemMedChem; 2010 Apr; 5(4):608-17. PubMed ID: 20183850
[TBL] [Abstract][Full Text] [Related]
4. Dual binding mode of a novel series of DHODH inhibitors.
Baumgartner R; Walloschek M; Kralik M; Gotschlich A; Tasler S; Mies J; Leban J
J Med Chem; 2006 Feb; 49(4):1239-47. PubMed ID: 16480261
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
6. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Hurt DE; Widom J; Clardy J
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):312-23. PubMed ID: 16510978
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans.
Zameitat E; Gojković Z; Knecht W; Piskur J; Löffler M
FEBS J; 2006 Jul; 273(14):3183-91. PubMed ID: 16774642
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
[TBL] [Abstract][Full Text] [Related]
9. Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction.
Inaoka DK; Sakamoto K; Shimizu H; Shiba T; Kurisu G; Nara T; Aoki T; Kita K; Harada S
Biochemistry; 2008 Oct; 47(41):10881-91. PubMed ID: 18808149
[TBL] [Abstract][Full Text] [Related]
10. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
14. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
16. Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.
Malmquist NA; Gujjar R; Rathod PK; Phillips MA
Biochemistry; 2008 Feb; 47(8):2466-75. PubMed ID: 18225919
[TBL] [Abstract][Full Text] [Related]
17. Site directed spin labeling studies of Escherichia coli dihydroorotate dehydrogenase N-terminal extension.
Couto SG; Cristina Nonato M; Costa-Filho AJ
Biochem Biophys Res Commun; 2011 Oct; 414(3):487-92. PubMed ID: 21986535
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Cordeiro AT; Feliciano PR; Pinheiro MP; Nonato MC
Biochimie; 2012 Aug; 94(8):1739-48. PubMed ID: 22542640
[TBL] [Abstract][Full Text] [Related]
19. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
20. Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii.
Hegewald J; Gross U; Bohne W
Mol Biochem Parasitol; 2013 Jul; 190(1):6-15. PubMed ID: 23747278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
